Your session is about to expire
← Back to Search
Ruxolitinib Cream for Atopic Dermatitis/Eczema (MORPHEUS Trial)
MORPHEUS Trial Summary
This trial tests a cream to see if it helps people with Atopic Dermatitis get better sleep.
MORPHEUS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMORPHEUS Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 49 Patients • NCT04839380MORPHEUS Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My itchiness level is 4 or higher.I have been diagnosed with active atopic dermatitis.I have not used any experimental drugs or devices in the last 4 weeks.My skin condition has significantly worsened or needed medication changes in the last 4 weeks.I have had PUVA treatment within the last 4 weeks.3-20% of my skin, except my scalp, is affected by atopic dermatitis.I stopped taking a JAK inhibitor due to side effects or intolerance.I have had Alzheimer's disease for at least 2 years.I have not used JAK inhibitors in the last 4 weeks.You have a score of 2 or higher on the IGA test during screening and baseline visits.I have not used UVB phototherapy or excimer laser in the last 4 weeks.I am willing to record my daily itch levels at the same time every day during the study.
- Group 1: Treatment Group: Ruxolitinib
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What dangers do participants face when given treatment with ruxolitinib?
"Our team has rated Ruxolitinib's safety a 3 based on the fact that this treatment is approved and currently undergoing Phase 4 trials."
Are more participants needed for this research endeavor?
"Affirmative. The information on clinicaltrials.gov implies that this research project is currently enrolling suitable participants. This trial, which was initially published on January 30th 2023 and amended most recently in mid-January, seeks 100 volunteers at two sites."
How many participants are currently enrolled in this experiment?
"Affirmative. According to information found on clinicaltrials.gov, this research is currently enrolling participants and has opened up recruitment since January 30th 2023. The last update was made January 13th of the same year with a goal of finding 100 people from two distinct sites."
Share this study with friends
Copy Link
Messenger